Fibrosis is caused by the proliferation of pathogenic myofibroblasts and the deposition of massive amounts of soluble collagen, altering the homeostasis of extracellular matrix (ECM) biogenesis and resulting in tissue scarring. Because a chromone scaffold (CS)-containing small molecule called eupatilin was shown to curb lung fibrosis, a new CS-containing analog, ONG41008, was generated. Plasma exposure was significantly increased. Orally-administered ONG41008 was more potent than pirfenidone at ameliorating fibrosis in a bleomycin-induced lung fibrosis model (BLM). ONG41008 also completely inhibited the trans-differentiation to myofibroblasts of ONGHEPA1, being a primary hepatic stellate cells (HSC) cell line, and of primary diseased human lung fibroblasts (DHLFs) derived from patients with idiopathic pulmonary fibrosis. ONG41008 inhibited the expression of LTBP1 and LAP, dismantling the latent TGF complex, likely limiting binding of TGF to TGF receptors I and II. ONG41008 also markedly inhibited the phosphorylation of SMAD2 and SMAD3, the induction of NADPH oxidase 4 (NOX4) in both cell types, and the production of reactive oxygen species.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a rare type of interstitial lung disease (ILD). 1 It is associated with high mortality and morbidity rates, with the median survival of patients with IPF ranging from 3~5 years after diagnosis and most patients dying within 5 years. 2 Nonalcoholic fatty liver disease (NAFLD) is becoming pandemic worldwide due to overnutrition. Nonalcoholic steatohepatitis (NASH) is an extreme manifestation of NAFLD, associated with various types of immunometabolic dysfunction, including steatosis, lobular inflammation and progressive fibrosis. 3, 4 Mitigation of liver fibrosis can inhibit the development of NASH. 5 The development of potent anti-fibrotic and anti-inflammatory agents is of paramount importance in the treatment of IPF and NASH. To date, however, no curative drugs for these conditions have become available. 6, 7 Two small-molecule anti-fibrotic drugs, pirfenidone (Esbriet) and nintedanib (Ofev), were recently approved for the treatment IPF, 8 but their efficacies and side effects must be improved to successfully treat these diseases. Moreover, the anti-fibrotic mechanism of action of pirfenidone remains to be determined.
Flavones are members of the polyphenol family, a group of >10,000 compounds predominantly found in the plant kingdom. 9 In general, these phytochemicals protect plants from radiation damage. 10 Due to their anti-oxidant and anti-inflammatory activities, flavones have long been used to treat inflammatory diseases such as arthritis and asthma 11 Chromone, 1,4-benzopyrone-4-one, is a central chemical scaffold for flavones, 12 with chromone scaffoldcontaining derivatives (CSD) being a diverse family, with branching chemical residues coupled to this core chemical scaffold. 13 We recently reported that eupatilin, a CSD from an Artemisia species, dramatically inhibits lipopolysaccharide (LPS)-induced osteoporosis, partially via actin depolymerization 14 and the downregulation of multiple genes associated with the epithelial-mesenchymal transition (EMT). The present study shows that a noble CSD, ONG41008, can block the induction of Type 2 EMT, also called fibrogenesis, arrest cell growth and alter cell morphology, thereby substantially ameliorating lung fibrosis. Its intrinsic potential that CD14 renders resistant to endocytosis may play a critical role in blocking LPSinduced activation followed by autoreactive-T cells-mediated hyper inflammation.
Results and Discussion
Non-GLP toxicokinetic studies in rats indicated that ONG41008 was present in plasma more than 12 hr after oral administration, resulting in a Tmax of 1-2 hr and a Cmax of 260.8  41.4 ng (Supplementary Figure S1A ). The tissue pharmacokinetics (PK) of orally administered ONG41008 in mice and rats over 2 hr were assessed. Oral gavage of ONG41008 for 14 days showed that this agent was non-toxic (data not shown), as was a single non-GLP dose in beagle dogs (Supplementary Figure S1B ).
Within 30 min after oral administration, ONG41008 was largely detected in plasma, lungs, liver, and kidneys of mice and rats (Supplementary Figure 2 ). Treatment of ONGHEPA1 primary (HSCs) line and primary diseased human lung fibroblasts (DHLFs) with transforming growth factor- (TGF) enhanced the expression of -smooth muscle actinin (SMA), but these increases were substantially mitigated by treatment with ONG41008 ( Figure 1A and 1B) .
Similarly, TGF induced expression of the pharmacodynamic markers Collagen111, Collagen11, and Periostin, but these increases were reduced by ONG41008, suggesting that ONG41008 may act directly on pathogenic myofibroblasts in both lung and liver fibrotic tissues. ONG41008 markedly inhibited the phosphorylation of both SMAD2 and SMAD3, not of ERK, suggesting that phosphorylated SMAD2 and/or SMAD3 may translocate to the nucleus, activating fibrogenesis, a process also called type II epithelial-to-mesenchymal transition (EMT)( Figure 1C ). Because eupatilin was able to depolymerize F-actin, we hypothesized that F-actin may be also a substrate for ONG41008. Under control conditions, Factin stress fibers were localized at cell focal adhesion regions ( Figure 1D ). Although treatment of ONGHAPA1 cells with ONG41008 resulted in massive actin depolymerization, this depolymerization did not occur in cells stimulated with the anti-IPF drugs pirfenidone and nintedanib, suggesting that these agents have no direct effects on actin in these cells. An in vitro actin polymerization/depolymerization assay showed that ONG41008 was a powerful inhibitor of actin polymerization ( Figure 1E ) as well as an enhancer of actin depolymerization ( Figure 1F ). To further assess the mechanism of action (MOA) of ONG41008, DHLFs treated with TGF and/or ONG41008 were stained with antibodies recognizing the components of the latent human TGF complex. Treatment with TGF markedly induced the expression of LTBP1 and LAP1 and their secretion into the extracellular matrix (ECM), whereas LTBP4 was only partially affected or unaffected by ONG41008 ( Figure 1G ). ONGHEPA1 cells converted to myofibroblasts by treatment with TGF for 24 hr and treated with TGF and ONG41008 for another 24 hr showed massive downregulation of LTBP1, LAP1, and integrin 53 expression, with these molecules confined to endosome-like vesicles, as well as the disappearance of actin stress fibers ( Figure 1H ). To identify the ONG41008-suppressible fibrosis-inducing genes (FIGS), DHLFs were differentially treated with TGF in the presence or absence of ONG41008 and transcriptomic changes were analyzed by RNA-seq analysis, using the selection process illustrated in Figure 2A . While seventy-seven ONG41008suppressible FIGS with p>0.005 were detected in DHLFs ( Figure 2B ) twenty-five FIGS were detected by ONG21001 (eupatilin) (Supplementary Figure S3 ), suggesting that, therapeutics per se, ONG41008 is three-fold as high as ONG21001. Many of those genes were previously found to be fibrogenic, including those encoding NOX4, CTGF, PERIOSTIN, LOX, and CDH2. [15] [16] [17] Induction of NOX4, which encodes NADPH oxidase 4, is associated with the production of reactive oxygen species (ROS) and with several important signaling events, including LPS signaling and inflammasome activation. 18 These findings suggested that NOX4 plays an important role in the pathogenesis of myofibroblasts. Interactome analysis showed that NOX4 was functionally related to endothelin (EDN) 1, connective tissue growth factor (CTGF) and insulin-like growth factor binding protein-3 (IGFBP-3) ( Figure 2C ). HSCs play a pivotal role in hepatic inflammation as well as liver fibrosis. 19, 20 To assess whether ONG41008 can suppress the induction of NOX4, thereby downregulating ROS production, ONGHEPA1 cells were treated with TGF, and the induction kinetics of NOX4 mRNA and protein, along with those of several fibrogenic genes, were analyzed. Nox4 mRNA and NOX4 polypeptide were significantly induced by TGF, with ONG41008 being able to block their induction, suggesting that ONG41008 inhibits the induction of NOX4 ( Figure 3A ). Immunocytochemistry (ICC; Figure 3B ) and ROS dye staining ( Figure 3D ) also showed that the production of ROS was significantly attenuated by ONG41008. Similar results were observed in DHLFs ( Figure 3C ). ONG41008 also blocked the induction of NOX4, CCL2, and CCL7 ( Figure 3E ), suggesting that ONG41008 could modulate the migration of macrophages to the liver.
Autophagy plays a pivotal role in attenuating fibrosis. 21, 22 To determine if ONG41008 could induce the induction of autophagosomes, DHLFs and ONGHEPA1 cells were treated with TGF plus ONG41008, resulting in the complete inhibition of fibrosis and of autophagosome production ( Figure 4A ). Western blotting of ONGHEPA1 cell lysates with a cleavage-specific anti-LC3 antibody showed fragmentation of LC3 protein, generating A/B polypeptide fragments ( Figure 4B ). Taken together, these findings indicate that ONG41008 is a potent anti-inflammatory drug as well as an inductor of autophagy, suggesting that ONG41008 may lessen the severity of IPF or liver inflammation such as NASH.
The therapeutic efficacy of ONG41008 in the treatment of IPF was analyzed in a bleomycin-induced lung fibrosis (BLM) model. Animals were orally administered 10-50mpk ONG41008, with 10 and 25mpk ONG41008, but not 50mpk ONG41008, effectively and significantly blocking the production of soluble collagen ( Figure 5A ). On the contrary, since 50mpk ONG41008 exhibited the most effective inhibitory capacity on hydroxyproline production. We speculate that the used mice colony for measuring soluble collagen might not properly respond to BLM. Pirfenidone tended to reduce soluble collagen and HP production, with collagen morphometry showing that 50mpk ONG41008 significantly inhibited the production of collagen and HP ( Figure 5B ). Furthermore 100mpk pirfenidone and 100mpk ONG41008 consistently inhibited in vivo TGF production (Supplementary Figure S4A) . A therapeutic BLM model was also tested, in which bleomycin was intratracheally administered for 1 week followed by daily oral administration of ONG41008 for 2 weeks. Maximal reduction of collagen production was observed at 50 and 100mpk ONG41008, but no significant inhibition was observed at 10mpk ONG41008 or 100mpk pirfenidone, suggesting that greater exposure to ONG41008 may be needed to cope with existing lung fibrosis. Although 10 and 50mpk ONG41008 tended to reduce the production of HP, 100mpk significantly inhibited HP production ( Figure 5C ). Expression of SMA were significantly lower in ONG41008-treated than in control mice. However, dexamethasone did not affect SMA staining, indicating that anti-inflammatory agents may be unable to mitigate the proliferation of myofibroblasts at advanced stages ( Figure 5D ).
Lung tissue PK experiments were performed to determine the percentage of parental compounds remaining 1 hr after oral administration 100mpk pirfenidone or ONG41008. The amount of ONG41008 was around ten-fold less than that of pirfenidone, suggesting that disease-correcting signaling associated with a given drug may a be more relevant index of its therapeutic efficacy than residual drug amounts (Supplementary Figure S4B ). Taken together, these findings suggest that ONG41008 may be a good candidate for treating IPF, either as monotherapy or in combination with pirfenidone.
The combined anti-inflammatory and anti-fibrotic activities of ONG41008 suggest that this agent may be ideal for the treatment of NASH, a challenging immunometabolic disease characterized by fatty liver, lobular inflammation, hepatocyte ballooning and progressive fibrosis. 4 23 Blockade of inflammation and/or fibrosis may therefore ameliorate NASH. The STAM mouse model, involving treatment for 5-8 weeks, resembles human NASH. 24 STAM mice were orally administered vehicle, 50mpk ONG41008, 30mpk telmisartan (positive control) or 30mpk obeticholic acid (OCA; negative control). Treatment with 50mpk ONG41008 improved fatty liver, whereas 30mpk OCA had no effect ( Figure 6A ). ONG41008 at a dose of 50mpk tended to reduce lobular inflammation and hepatocyte ballooning, whereas 30mpk OCA tended to inhibit fibrosis. Telmisartan clearly improved all parameters ( Figure 6A and 6B). Pathologic manifestations were given NAFLD scores, with 1 indicating steatosis, two indicating lobular inflammation and three as hepatocyte ballooning and hepatic fibrosis ( Figure   6C ). Close pathological examination revealed that ONG41008 and telmisartan were therapeutically effective for NASH based on NAFLD scores ( Figure 6D ).
Considering all these results, we established an integrative view on anti-inflammatory and anti-fibrotic capabilities associated with ONG41008 ( Figure 7 ).
Because we assessed the anti-inflammatory activity of ONG41008 in TGF-treated HSCs and DHLFs, it was unclear whether its anti-inflammatory activity was applicable to LPStreated macrophages in the absence of TGF. RAW264.7 cells, a mouse monocytic leukemic cell line resembling macrophages, were stimulated with LPS in the presence or absence of ONG41008. The expression of mRNAs encoding proinflammatory cytokines and chemokines, including TNF, IL-1, CCL2, CCL7, and CXCL2, was markedly downregulated ( Figure 8A -E), as was the expression of CHOP and NOX1, suggesting that ONG41008 inhibits inflammasome formation ( Figure 8F,G) . [25] [26] [27] However, the expression of IL6 and IL23 was not significantly reduced (data not shown). TNF ELISA showed that TNF protein levels were clearly reduced ( Figure 8H ). ONG41008 effectively blocked the expression of TNF induced by varying concentrations of LPS, ranging from 100 ng/ml to 10 g/ml, suggesting that some membrane proximal events may be responsible for the ONG41008-mediated inhibition of TNF gene expression (Supplementary Figure S5) and that ONG41008 may inhibit the formation of TLR4-LPS binding proteomes or signalosomes, such as CD14, MD-2 or Myd88. 28 A number of the human TLR family members utilize CD14 as a coreceptor. Assessment of the intracellular trafficking of these proteins upon LPS stimulation showed endocytosis of CD14 alone in response to LPS followed by its redistribution in the plasma membrane ( Figure 9A ).
Magnified views further revealed that endocytosis was coupled with CD14 relocation to the plasma membrane ( Supplementary Figures S5A-C) . By contrast, MD-2, TLR4, Myd88, and NOX4 remained unaltered (Supplementary Figure S8) . In sum, stimulation of RAW264.7 cells with LPS in the presence of ONG41008 resulted in the rapid endocytosis and redistribution of CD14 to the plasma membrane. While LPS rapidly upregulated CD14 treatment with ONG41008 remained unchanging ( Figure 9B ). Taken together, these findings indicate that ONG41008 is an endocytosis inhibitor of CD14, as illustrated in Figure 9C .
In conclusion, we describe a CS-containing small molecule, ONG41008, with both anti-fibrotic and anti-inflammatory activities. ONG41008 may ameliorate a broad range of fibrotic conditions, such as fibrosis of the heart and kidneys, macular fibrosis, and NASH, as well as fibrotic cancers such as pancreatic cancer. In addition to these generalized antiinflammation via innate immunity ONG41008 may be an effective modality for autoreactive peripheral or central T cells-mediated hyper inflammation. 
Figure legends

Materials and Methods
Cell culture and reagents
DHLFs were purchased from Lonza (Basel, Switzerland) and cultured in fibroblast growth medium (FBM, Lonza, Walkersville, MD, USA). Recombinant human TGF- and PDGF were obtained from Peprotech (Rocky Hill, CT, USA) and used at final concentrations of 5 ng/ml.
Chemically synthesized ONG41008 was obtained from Syngene International Ltd. (Bangalore, India), dissolved at a stock concentration of 50 mM in DMSO, and stored in aliquots at -20C.
DMSO with was used as control. RAW264.7 cells were purchased from the Korean Cell Line Bank (Seoul, Korea) and cultured in RPMI supplemented with 10% FBS and 1% P/S (Welgene, Seoul, Korea). LPS was purchased from Sigma and used at a final concentration of 100 ng/ml.
Effects of drugs on bleomycin-induced lung tissue fibrosis
C57BL/6J mice were anesthetized by inhalation of 70% N2O and 30% O2 gas containing 1.5% isoflurane. Fifty microliters of bleomycin solution in distilled water was directly injected into their lungs via the aperture. The mice were allowed to recover from the anesthetic and then housed in normal cages. Bleomycin (0.03 U in 50 µl saline) was administered once using a visual instillobot. Seven days after the administration of bleomycin, mice were orally administered with 10 to 100mpk ONG41008 dissolved in 0.5% CMC containing 1% Tween80 via a micropipette, once daily for 2 weeks. For 2 to 3 days after administration of eupatilin, the mice were monitored for toxic symptoms or death, but no abnormal symptoms were observed. One hour before sacrifice, a final dose of ONG41008 or pirfenidone was administered for plasma or lung PK. Ten mice per test group were selected, and their lung tissues were excised, stained with Masson's trichrome and observed under a microscope.
Results were expressed as mean and standard deviation. Data from control and eupatilin-treated mice were compared using Student's t-test, with p<0.05 considered statistically significant.
RNA-seq processing, differential gene expression analysis, and interactome analysis
Processed reads were mapped to the Mus musculus reference genome (Ensembl 77) using Tophat and Cufflink with default parameters. Differential analysis was performed using Cuffdiff with default parameters. FPKM values from Cuffdiff were normalized and quantitated using the R Package Tag Count Comparison (TCC) to determine statistical significance (P values) and differential expression (fold changes). Gene expression was plotted as fold-changes using Scatter, MA, and Volcano plots, using an R script developed in-house. The protein interaction transfer procedure for the differentially expressed genes was performed using the STRING database. A 60 Gb sequence was generated, and 10,020 transcripts were read and compared. The highest-confidence interaction score (0.9) was applied from Mus musculus, and information about interacts were obtained based on text mining, experiments, and databases (http://www.string-db.org/).
Reverse transcriptase PCR and real-time PCR
Cells cultured in either 12-or 24-well plates were washed twice with cold PBS and harvested using TaKaRa MiniBEST Universal RNA extraction kits (Takara, Japan). Total RNA was purified using the same kits according to the manufacturer's protocol. RNA was reversetranscribed using cDNA Synthesis Kits (PCRBio Systems, London, UK), followed by amplification with StepOne Plus (Applied Biosystems, Life Technologies) and 2× qPCRBio Probe Mix Hi-ROX (PCRBio). mRNA levels were compared using the ∆∆Ct method, with GAPDH mRNA as the internal control.
ELISA and immunoblotting
Mouse TNFα Quantine ELISA kits were purchased from R&D Systems (Minneapolis, MN, USA). Raw264.7 cells were seeded at 1 × 10 5 cells/well in 12-well cell culture plates and 
